TLDR JAK inhibitors effectively treat skin conditions and topical forms are safer.
Janus Kinase (JAK) inhibitors were found to be effective in treating various immune-related dermatological conditions, including atopic dermatitis, alopecia areata, psoriasis, and vitiligo, by blocking cytokine functions and gene transcription related to inflammation and immunity. While oral administration of JAK inhibitors was common, concerns about side effects led to the exploration of topical formulations, which appeared to be safe, well-tolerated, and a promising alternative.
40 citations
,
August 2022 in “Frontiers in immunology” Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
489 citations
,
November 2021 in “Signal Transduction and Targeted Therapy” The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
40 citations
,
June 2021 in “Clinical, cosmetic and investigational dermatology” JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
November 2025 in “Journal of Clinical Medicine” Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
1 citations
,
August 2023 in “Biomolecules” Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.
MagicBold